Fast Five Quiz: Castration-Resistant Prostate Cancer

Kyle A. Richards, MD


December 02, 2020

Apalutamide, enzalutamide, and darolutamide all appear safe and well tolerated. Quality-of-life studies suggest no significant negative effects, and patients generally do well. All three agents cause fatigue and worsen hot flashes. In the SPARTAN trial, 25% of patients treated with apalutamide for nmCRPC experienced mild rash compared with 5% who received placebo.

Enzalutamide caused fatigue in about one third of patients compared with 14% with placebo. Darolutamide was not associated with any significant increases in side effects compared with placebo.

Learn more about the safety profile of apalutamide, enzalutamide, and darolutamide.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.